SBIR/STTR Research Award

PRODUCTION OF AMONOCLONAL ANTIBODY BASE SANDWICH ASSAY

Award identifier 32c700bdd087a979f5e72be0972a9ca409ded529eb76a56ffc26ae64471c225cAwarding agency Department of Health and Human Services

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

1994

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Angel Wings Technology
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE GOAL OF THE RESEARCH IS TO GENERATE DIAGNOSTIC REAGENTS AND/OR THERAPEUTIC REAGENTS FOR DIABETES THROUGH PRODUCTION OF MONOCLONAL ANTIBODIES TO THE PEPTIDE HORMONE, AMYLIN. AMYLIN IS A NEWLY DISCOVERED PEPTIDE HORMONE THAT IS ACTIVE IN THE CONTTROL OF GLUCOSE METABOLISM AND THE MEASUREMENT OF PEPTIDE LEVELS DIRECTLY IN PLASMA WILL BE KEY TO FURTHER UNDERSTANDING AND QUANTITATING THE ROLE THAT THE HORMONE PLAYS IN THE DISEASE PROCESSES OF TYPE I AND TYPE II DIABETES, MONOCLONAL ANTIBODY REAGENTS WILL I) ASSURE STABLE SUPPLIES OF HIGH AFFINITY ANTIBODIES SPECIFIC TO DIFFERENT EPITOPES ON THE AMYLIN PROTEIN, II) BE USED TO MAKE ISOTOPE OR ENZYME CONJUGATED ANTIBODIES SPECIFIC FOR AMYLIN AND, III) BE USEFUL FOR THE DEVELOPMENT OF A SANDWICH ASSAY FOR AMYLIN. DURING PHASE I, WE WILL CHARACTERIZE THE MONOCLONAL ANTIBODIES PRODUCED FOR: I) SPECIFICITY TO AMYLIN, II) APPARENT AFFINITY CONSTANT, III) EPITOPE MAPPING USING PEPTIDE FRAGMENTS, IV) ABILITY TO FORM A COMPLEX WITH OTHER MONOCLONAL ANTIBODIES AND/OR AVAILABLE POLYCLONAL ANTISERA, V) IMMUNOGLOBULIN SUBTYPE. IN PHASE II, WE WILL USE THESE REAGENTS TO I) DEVELOP A SANDWICH ASSAY FOR AMYLIN, II) CONSTRUCT AN AFFINITY COLUMN TO PURIFY AND FURTHER CHARACTERIZE AMYLIN FROM HUMAN PLASMA: III) IDENTIFY ANTIBODIES THAT BLOCK AMYLIN BINDING TO ITS RECEPTOR AND USE THESE ANTIBODIES TO MODULATE AMYLIN ACTION IN VIVO: IV) CHARACTERIZE THE METABOLIC PRODUCTS OF AMYLIN.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.